These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 24759294

  • 1. Tasimelteon (Hetlioz) for non-24-hour sleep-wake disorder.
    Med Lett Drugs Ther; 2014 Apr 28; 56(1441):34-5. PubMed ID: 24759294
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.
    Stahl SM.
    CNS Spectr; 2014 Dec 28; 19(6):475-8. PubMed ID: 25422900
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.
    Lockley SW, Dressman MA, Licamele L, Xiao C, Fisher DM, Flynn-Evans EE, Hull JT, Torres R, Lavedan C, Polymeropoulos MH.
    Lancet; 2015 Oct 31; 386(10005):1754-64. PubMed ID: 26466871
    [Abstract] [Full Text] [Related]

  • 7. Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals.
    Keating GM.
    CNS Drugs; 2016 May 31; 30(5):461-8. PubMed ID: 27003694
    [Abstract] [Full Text] [Related]

  • 8. Tasimelteon approved for circadian disorder in blind adults.
    Traynor K.
    Am J Health Syst Pharm; 2014 Mar 01; 71(5):350. PubMed ID: 24534583
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder.
    Johnsa JD, Neville MW.
    Ann Pharmacother; 2014 Dec 01; 48(12):1636-41. PubMed ID: 25204464
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies.
    Leger D, Quera-Salva MA, Vecchierini MF, Ogrizek P, Perry CA, Dressman MA.
    Expert Opin Drug Saf; 2015 Dec 01; 14(11):1673-85. PubMed ID: 26393492
    [Abstract] [Full Text] [Related]

  • 17. Out of synch with society: an update on delayed sleep phase disorder.
    Nesbitt AD, Dijk DJ.
    Curr Opin Pulm Med; 2014 Nov 01; 20(6):581-7. PubMed ID: 25160887
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Refractory Insomnia in an Adolescent with Total Blindness.
    Tubbs AS, Grandner MA, Combs D.
    Yale J Biol Med; 2019 Jun 01; 92(2):201-204. PubMed ID: 31249480
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.